

Breast Cancer Screening

©2013 Truven Health Analytics Inc. Proprietary and confidential.

MEASURE DESCRIPTION:

Breast Cancer Screening indicates whether a woman member, aged 42 to 69 years, had a mammogram done during the measurement year or the year prior to the measurement year. This excludes women who had a bilateral mastectomy or two unilateral mastectomies.

This measure is based on the HEDIS measure *Breast Cancer Screening* (BCS).

PROPRIETARY STATUS: This measure is owned by CMS/NCQA [NQF-Endorsed™].

CRITERIA REVISION:

- This measure is based on the HEDIS® 2013 Technical Specifications for Physician Measurement criteria.

CRITERIA REVIEW DATE: 04/04/2013

MEASURE TYPE:

MEASURE PACKAGE: Advantage Nationally Endorsed

MINIMUM DATA REQUIREMENTS (months): 24

MEASURE DETAILS:

DENOMINATOR:

Identifies women members, aged 42 to 69 years. Because this measure looks back 24 months for a mammogram, the eligible population includes women who could have been 40 years of age at the time of the mammogram. This measure excludes women who had a bilateral mastectomy or 2 unilateral mastectomies.

Age in years (as of the end of the measurement year) and Gender	Age in Years = 42-69 And Gender Code = F
--	--

EXCLUSIONS:

Excludes from the eligible population those women who had a bilateral mastectomy or a right and left unilateral mastectomy anytime prior to or during the measurement year (based on claims included in the database). Note: NCQA specifies that the mastectomy exclusion criteria should only be applied if a woman has not had a mammogram. This initial check for a mammogram has not been implemented.

Bilateral mastectomy (anytime prior to or during the measurement year)	ICD-9 Procedure Code = 85.42, 85.44, 85.46, 85.48 Or (CPT Procedure Code = 19180, 19200, 19220, 19240, 19303-19307 And Procedure Modifier Code 1, 2, 3, or 4 = 50)
OR	
A previous right unilateral mastectomy and a previous	ICD-9 Procedure Code = 85.41, 85.43, 85.45, 85.47

left unilateral mastectomy (anytime prior to or during the measurement year)	Or (CPT Procedure Code = 19180, 19200, 19220, 19240, 19303-19307) And Procedure Modifier Code 1, 2, 3, or 4 = RT) And (CPT Procedure Code = 19180, 19200, 19220, 19240, 19303-19307) And Procedure Modifier Code 1, 2, 3, or 4 = LT)
--	---

NUMERATOR:

Identifies women members, aged 42 to 69 years, who had a mammogram done during the measurement year or the year prior to the measurement year.

Mammogram performed (during the measurement year or the year prior)	CPT Procedure Code = 76083, 76090-76092, 77055-77057 Or HCPCS Procedure Code = G0202, G0204, G0206 Or ICD-9 Procedure Code = 87.36, 87.37 Or Revenue Code UB = 0401, 0403
--	---

CONTINUOUS ENROLLMENT:

Continuously enrolled with medical coverage during the measurement year and the year prior to the measurement year, which equates to 24 months out of 24 months.

MEASURE BACKGROUND:

Breast cancer is the most common non-skin cancer and the second-deadliest cancer for women in the United States. Approximately 230,000 women in the U.S. are diagnosed with invasive breast cancer every year.

There is more scientific evidence supporting the screening for breast cancer than for any other cancer. The relevant issues mentioned about breast cancer screening include the method of screening, the age to begin, the age to stop, and the frequency of screening. With respect to the method of screening, mammography is the "gold standard". While several imaging technologies (e.g., MRI) are under study, current evidence is insufficient to recommend any of these technologies for general population screening. There is strong consensus for routine screening during the ages of 50 to 69. The benefits are not as clear for routine screening in women ages 40 to 49. The issues for screening women ages 40 to 49 revolve around the incidence of breast cancer, the cost-effectiveness of the study, the number of false positives and related additional mammography and biopsies, and the increased radiation exposure. The United States Preventive Services Task Force (USPSTF), the American College of

Physicians, and the Canadian Task Force on the Periodic Health Examination recommend breast cancer screening to start at age 50 years, although many organizations, including the American Cancer Society, the American College of Radiology, the American Medical Association, the National Cancer Institute, the American College of Obstetricians and Gynecologists, and the National Comprehensive Cancer Network (NCCN) recommend starting at age 40 years for average-risk patients. The usual recommended interval is 1 to 2 years.

Most studies have included women up to age 69, so there is less data on when to stop screening. The consensus seems to be that breast cancer screening should be continued as long as a woman has a life expectancy of at least 5 years. The recent USPSTF guideline recommends mammograms until age 74 years. The HEDIS measure specifications are for screening ages 40 to 69 years.

AMA PCPI Notice of Use. Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

The Measures are provided as is without warranty of any kind. ©2007 American Medical Association. All Rights Reserved.

CPT® copyright 2012 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Applicable FARS/DFARS restrictions apply to government use.

CPT is a registered trademark of the American Medical Association.

The LOINC® codes, LOINC® table (regardless of format), LOINC® Release Notes, LOINC® Changes File, and LOINC® Users Guide are copyright© 1995-2012, Regenstrief Institute, Inc., and the Logical Observation Identifiers Names and Codes (LOINC) Committee. All rights reserved.

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not commercial use. Commercial use of a measure does require the prior written consent of the measure developer. As used herein, a • commercial use• refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain (even if there is no actual charge for inclusion of the measure).

These performance measures were developed and are owned by the National Committee for Quality Assurance (• NCQA•). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA.

© 2009-2012 National Committee for Quality Assurance. All rights reserved.

RED BOOK™ is a trademark of Truven Health Analytics Inc.
